Literature DB >> 17276731

Tipping the gatekeeper: S1P regulation of endothelial barrier function.

Hugh Rosen1, M Germana Sanna, Stuart M Cahalan, Pedro J Gonzalez-Cabrera.   

Abstract

The lysophospholipid sphingosine 1-phosphate (S1P) is a pleiotropic signaling lipid present constitutively in plasma, and secreted locally at elevated concentrations at sites of inflammation. S1P maintains essential variable homeostatic functions in addition to inducing pathophysiology through the activation of five specific high-affinity G-protein-coupled receptors. Therefore, S1P can function as an extracellular rheostat regulating tonic and acutely evoked functions. Although S1P receptors can regulate lymphoid development and lymphocyte trafficking, and different opinions exist on the roles of receptor agonism and functional antagonism in regulating lymphocyte recirculation, this personal perspective highlights the pivotal control points regulated by constitutive and induced S1P receptor tone at vascular endothelial and lymphatic endothelial barriers, through which S1P agonism impacts on both innate and adaptive immunity. We also emphasize how specific, proof-of-concept chemical tools complement genetic approaches by enabling reversible perturbation of the S1P-S1P(1) receptor axis and, thus, clarifying in vivo mechanisms in the absence of developmental compensations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276731     DOI: 10.1016/j.it.2007.01.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  81 in total

Review 1.  Shaping the landscape: metabolic regulation of S1P gradients.

Authors:  Ana Olivera; Maria Laura Allende; Richard L Proia
Journal:  Biochim Biophys Acta       Date:  2012-06-23

2.  Sphingosine-1-phosphate prevents permeability increases via activation of endothelial sphingosine-1-phosphate receptor 1 in rat venules.

Authors:  Gengqian Zhang; Sulei Xu; Yan Qian; Pingnian He
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

Review 3.  Influenza lung injury: mechanisms and therapeutic opportunities.

Authors:  David J Gregory; Lester Kobzik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-25       Impact factor: 5.464

4.  Granule-mediated release of sphingosine-1-phosphate by activated platelets.

Authors:  Deepa Jonnalagadda; Manjula Sunkara; Andrew J Morris; Sidney W Whiteheart
Journal:  Biochim Biophys Acta       Date:  2014-08-23

Review 5.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 6.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

Review 7.  Choreography of cell motility and interaction dynamics imaged by two-photon microscopy in lymphoid organs.

Authors:  Michael D Cahalan; Ian Parker
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 8.  Geography and plumbing control the T cell response to infection.

Authors:  Kamal M Khanna; Leo Lefrançois
Journal:  Immunol Cell Biol       Date:  2008-04-08       Impact factor: 5.126

9.  Fingolimod treatment in multiple sclerosis leads to increased macular volume.

Authors:  Rachel Nolan; Jeffrey M Gelfand; Ari J Green
Journal:  Neurology       Date:  2012-12-05       Impact factor: 9.910

10.  Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice.

Authors:  Eric Camerer; Jean B Regard; Ivo Cornelissen; Yoga Srinivasan; Daniel N Duong; Daniel Palmer; Trung H Pham; Jinny S Wong; Rajita Pappu; Shaun R Coughlin
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.